SHBG: What Your Number Changes About Your Treatment

What SHBG actually does to your hormones

SHBG is a glycoprotein made mainly by the liver that binds circulating sex steroids. In men, the large majority of circulating testosterone is bound to SHBG or loosely bound to albumin, with only a small percentage truly free; the free plus albumin-bound fractions together are usually called "bioavailable" testosterone, the portion available to reach androgen receptors. Exact percentages vary by study and method, and readers should treat any single precise figure (for example "1 to 3 percent free") as a commonly cited approximation rather than a fixed constant.

SHBG's binding is not simple storage. It has somewhat higher affinity for testosterone than for estradiol, so a change in SHBG concentration can shift the effective testosterone-to-estradiol balance even when total hormone production is unchanged. Two patients with the same total testosterone can have meaningfully different calculated free testosterone if their SHBG levels differ substantially.

Clinical endocrinology guidance on testosterone therapy generally recommends measuring SHBG in situations where total testosterone may not reflect free testosterone well, including obesity, aging, diabetes, and thyroid disease. That describes a large share of patients seen in hormone optimization or menopause care, which is why SHBG is often ordered alongside total testosterone or estradiol rather than as a standalone test.

SHBG also responds to metabolic signals. Insulin is understood to suppress hepatic SHBG production. This creates a loop worth knowing about: insulin resistance tends to push SHBG down, which raises the free fraction of circulating androgens, a relationship relevant both to polycystic ovary syndrome (PCOS) in women and to increased peripheral estrogen conversion in men.

Should you trust a "normal" SHBG result?

Reference ranges are population averages, not symptom thresholds. A person whose SHBG sits comfortably inside the standard range can still have calculated free testosterone or free estradiol below the level associated with symptoms, because the reference range was built from a general population, not from people matched on symptoms.

Age changes this further. Observational cohort research in aging men has generally found that SHBG rises gradually with age, while total testosterone declines only modestly in otherwise healthy men. Because SHBG rises while total testosterone barely moves, much of the free-testosterone decline attributed to "low T" in older men is plausibly driven by rising SHBG rather than by falling total production. This is a widely cited interpretation in the literature, though the exact magnitude of SHBG's age-related rise varies across studies and should not be quoted as a fixed percentage without checking the specific cohort.

Women show an even wider physiological range. Premenopausal women taking combined oral contraceptives commonly have markedly elevated SHBG, because ethinylestradiol is a potent stimulator of hepatic SHBG synthesis. After menopause, SHBG typically falls unless oral estrogen replacement raises it again. The practical question is never whether a number falls inside a printed reference interval; it is whether that SHBG level plausibly explains a mismatch between measured total hormone and reported symptoms.

SHBG-driven prescribing decision map

The table below is a starting framework for a clinician-patient conversation, not a self-treatment protocol. It assumes total testosterone or total estradiol has already been measured and pairs it with SHBG to flag what usually needs to happen next. Exact numeric thresholds vary by lab and should be confirmed against your own lab's reference range and a clinician's judgment.

How high SHBG changes prescribing

When SHBG is elevated, the effective free hormone pool shrinks even if total hormone looks adequate.

TRT in men with high SHBG. Testosterone injections can temporarily saturate SHBG binding around the injection but leave wider troughs as SHBG recaptures free testosterone between doses. Guideline-level discussion of testosterone therapy generally notes that injectable testosterone produces substantial peak-to-trough fluctuation, and that men with high SHBG may do better with more frequent, smaller doses (for example twice-weekly subcutaneous injections) or daily transdermal gel to keep free testosterone steadier. Some clinicians favor subcutaneous pellets for this reason, though pellets carry their own tradeoffs (minor surgical insertion, less ability to adjust dose mid-cycle) that should be discussed directly with a prescriber.

HRT in women with high SHBG. Oral estradiol raises SHBG because of first-pass hepatic metabolism; transdermal estradiol largely avoids this effect. Trial evidence in recently postmenopausal women (the KEEPS trial) is often cited to show that oral conjugated equine estrogen raises SHBG substantially over several years while transdermal estradiol does not meaningfully change it. For a woman who already runs high SHBG, transdermal estradiol avoids compounding the problem.

Thyroid connection. Hyperthyroidism is a well-established driver of elevated SHBG, and correcting the thyroid disorder often normalizes SHBG without any hormone-therapy intervention. TSH should be checked before attributing an elevated SHBG to an intrinsic hepatic or aging effect.

How low SHBG changes prescribing

Low SHBG inflates the bioavailable fraction of whatever sex steroid is circulating, which creates a different set of problems.

Metabolic syndrome link. Lower SHBG is consistently associated with higher risk of insulin resistance and type 2 diabetes in both observational cohorts of women and men. The relationship is generally described as bidirectional: insulin resistance suppresses SHBG, and low SHBG is also treated as an independent risk marker in its own right. Readers should treat any specific odds ratio quoted for this relationship as needing verification against the primary study rather than repeating it as an exact, load-bearing number.

TRT dose risk. Men with low baseline SHBG who start a standard testosterone dose can develop free testosterone well above the reference range even though total testosterone looks unremarkable. This raises practical risk of erythrocytosis, acne, and increased peripheral aromatization to estradiol. A cautious, commonly used approach is to start below the standard starting dose and check free testosterone earlier than the usual follow-up interval, though the specific starting dose should be set by the prescribing clinician based on the individual's full picture, not from a generic number in an article.

PCOS and low SHBG. In women with PCOS, low SHBG amplifies the clinical effect of even a modestly elevated total testosterone. Guideline-level PCOS recommendations support using a calculated free androgen index (FAI = total testosterone divided by SHBG, times 100) as a more sensitive marker of hyperandrogenism than total testosterone alone.

Estradiol management. Low SHBG raises free estradiol along with free testosterone. In men on TRT this can produce gynecomastia or fluid retention at total estradiol levels that would otherwise look acceptable, which is why some clinicians monitor free or sensitive (LC-MS/MS) estradiol rather than relying on a standard total estradiol assay when SHBG is low.

What moves SHBG up or down

Knowing the inputs lets a patient and clinician anticipate an SHBG shift instead of discovering it after the fact.

Commonly cited upward drivers: oral estrogen-containing medications (birth control pills, oral estradiol HRT), hyperthyroidism, hepatitis or cirrhosis, aging, prolonged caloric restriction, and certain anticonvulsants such as phenytoin and carbamazepine. Meaningful weight loss achieved through sustained caloric deficit can raise SHBG enough that a man on stable TRT may need a dose review to keep free testosterone in range.

Commonly cited downward drivers: insulin resistance and hyperinsulinemia, obesity (particularly visceral fat), hypothyroidism, exogenous androgenic compounds (including testosterone therapy itself), nephrotic syndrome, and acromegaly.

GLP-1/GIP receptor agonists such as semaglutide and tirzepatide (FDA-approved for type 2 diabetes and, in higher-dose formulations, for chronic weight management as of this writing) improve insulin sensitivity and reduce visceral fat in trial populations. Because insulin suppresses SHBG, it is biologically plausible that these medications raise SHBG indirectly as metabolic status improves. This is a reasonable inference from the known insulin-SHBG relationship, not a directly demonstrated trial endpoint; SHBG has generally not been a prespecified outcome in the major weight-loss trials for these drugs, so this connection should be described as plausible rather than established.

Oral vs. transdermal estrogen: when SHBG tips the decision

Route of estrogen administration is one of the more consequential prescribing decisions that SHBG influences. Oral estradiol goes through first-pass hepatic metabolism, which stimulates SHBG along with clotting factors and C-reactive protein. Transdermal estradiol bypasses the liver on first pass and does not raise SHBG to the same degree.

This distinction has a documented safety dimension. Case-control research comparing oral and transdermal hormone therapy has generally found a higher venous thromboembolism risk with oral estrogen than with transdermal estrogen, a difference commonly linked to the same first-pass hepatic effect that raises SHBG and clotting factors together. Exact risk ratios from any single study should be verified against the primary paper before being used to counsel an individual patient, since case-control estimates vary by population and era.

For a woman starting HRT with an already-elevated baseline SHBG, transdermal estradiol is generally the preferred route because it avoids amplifying SHBG further and preserves more free estradiol. For a woman with low SHBG and signs of androgen excess (acne, hirsutism, androgenic alopecia), oral estradiol's SHBG-raising effect can be used deliberately, because raising SHBG reduces the free androgen fraction. That tradeoff (androgen benefit vs. clot risk) needs to be weighed individually and is a reasonable conversation to have directly with a prescriber rather than a default choice.

The core, quotable relationship here: SHBG is not a hormone itself, it is the binding protein that determines what fraction of circulating testosterone and estradiol is actually free to act on tissue, so identical total hormone levels can produce different symptoms and different treatment needs depending on SHBG. This is established physiology and the basis for pairing SHBG with total hormone measurement whenever a total testosterone or estradiol result does not match the clinical picture.

How SHBG-based free testosterone calculations work, and where they break

Most labs do not measure free testosterone directly. Instead they calculate it from total testosterone, SHBG, and albumin using an established equation (commonly the Vermeulen method). This calculation is reasonably reliable when all three inputs are drawn from the same blood sample, but it is an estimate, not a direct measurement, and it can be less accurate at the extremes of SHBG.

Equilibrium dialysis is generally regarded as the reference-standard method for free testosterone but is expensive, slow, and offered by few reference laboratories, which is why calculated free testosterone is used in routine practice. Direct analog free testosterone immunoassays are widely considered unreliable for clinical decision-making and are not recommended by major endocrine guidance; if a lab report shows a free testosterone result and you are unsure which method was used, it is worth asking.

For men on TRT, a practical monitoring pattern is total testosterone, SHBG, and albumin drawn together at baseline and at follow-up visits after any dose change, then periodically once stable. A calculated free testosterone below the lab's lower reference limit in someone with ongoing symptoms suggests the current dose may be inadequate, regardless of what the total testosterone number shows.

For women, free testosterone concentrations sit near the lower detection limit of many assays, which makes direct measurement less reliable. The free androgen index (FAI) is a commonly used surrogate when equilibrium dialysis is not available.

Monitoring SHBG during treatment

SHBG is not a check-once value. It moves with body composition, insulin sensitivity, thyroid status, and the hormones being prescribed, so a monitoring rhythm built around key inflection points helps avoid both under- and over-treatment.

• Baseline, before starting any hormone therapy, to establish metabolic context and guide initial formulation and dose.
• Roughly 6 to 12 weeks after starting or changing therapy, to recalculate free testosterone or free estradiol with the updated SHBG. Exogenous testosterone can suppress SHBG somewhat in the first few months of therapy; oral estrogen tends to raise it within weeks.
• After a significant weight change, since meaningful weight loss (particularly loss of visceral fat) can raise SHBG enough to change free hormone levels even if the prescribed dose has not changed.
• After a thyroid status change, since correcting hypothyroidism raises SHBG and correcting hyperthyroidism lowers it; rechecking SHBG some weeks after a thyroid medication adjustment is reasonable.
• Annually once stable, to confirm that no quiet metabolic drift is silently altering the free hormone fraction.

What is established, what is plausible, and what is not established

Established: SHBG binds testosterone and estradiol and limits their free, biologically active fraction; oral estrogen raises SHBG more than transdermal estrogen because of first-pass hepatic metabolism; insulin suppresses hepatic SHBG production; hyperthyroidism raises SHBG and hypothyroidism lowers it; direct analog free testosterone immunoassays are unreliable for clinical decisions.

Plausible but not fully proven at the individual-patient level: that GLP-1/GIP medications raise SHBG meaningfully as a downstream effect of improved insulin sensitivity (biologically consistent, not a demonstrated trial endpoint); that specific numeric SHBG cutoffs (for example "above 50 nmol/L" or "below 20 nmol/L") predict symptoms reliably across individuals, when in practice these are population-derived heuristics rather than validated decision thresholds; that supplements marketed to lower or raise SHBG (such as boron) produce clinically meaningful, durable change outside small studies.

Not established from the material available here: precise effect sizes (odds ratios, percentage changes) for several of the relationships described above, which should be verified against the primary literature before being used to counsel a specific patient rather than repeated as fixed figures.

When to seek urgent care rather than adjust hormone therapy at home

SHBG and free hormone imbalances are not emergencies on their own, but some associated symptoms are. Seek urgent evaluation for chest pain, sudden shortness of breath, one-sided leg swelling or pain (possible blood clot, relevant to oral estrogen users), sudden vision changes, or severe mood or behavioral changes that feel unsafe. These require direct medical evaluation rather than a lab-value adjustment.

A note on evidence and sources

This article describes generally accepted physiology of SHBG (its binding role, its relationship to insulin and thyroid status, and the oral-versus-transdermal estrogen distinction) using language calibrated to how confidently each claim is supported. Several specific numbers that commonly circulate in SHBG discussions, including precise odds ratios, percentage changes with weight loss, and exact age-related rise in SHBG, are described here in general terms rather than as fixed figures, because they should be checked against the specific primary study before being used to counsel an individual patient. Quotations attributed to named clinicians or guideline bodies in earlier versions of hormone-education material of this type often cannot be verified word-for-word against a public source, so this draft paraphrases guidance rather than presenting quoted language, and flags this as a point requiring confirmation during medical review. Nothing in this article is individualized dosing advice; testosterone therapy, estrogen therapy, and GLP-1 medications each carry their own FDA-approved indications, contraindications, and monitoring requirements that a prescribing clinician should walk through directly with the patient.